Biophytis SA
PAR:ALBPS
Biophytis SA
Research & Development
Biophytis SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biophytis SA
PAR:ALBPS
|
Research & Development
-€3.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Research & Development
-€119.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Research & Development
-€40.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Research & Development
-€86.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Research & Development
-$95.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-16%
|
|
|
Abivax SA
PAR:ABVX
|
Research & Development
-€199.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biophytis SA
Glance View
Biophytis SA is a holding company. The company is headquartered in Paris, Ile-De-France and currently employs 24 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
See Also
What is Biophytis SA's Research & Development?
Research & Development
-3.2m
EUR
Based on the financial report for Jun 30, 2025, Biophytis SA's Research & Development amounts to -3.2m EUR.
What is Biophytis SA's Research & Development growth rate?
Research & Development CAGR 5Y
24%
Over the last year, the Research & Development growth was 63%. The average annual Research & Development growth rates for Biophytis SA have been 49% over the past three years , 24% over the past five years .
